10-Q: Arcturus Therapeutics Reports Q1 2025 Financial Results, Highlights KOSTAIVE Approval and Clinical Program Advancements

Arcturus Therapeutics announces its Q1 2025 financial results, emphasizing the commercialization of KOSTAIVE and progress in its mRNA therapeutics pipeline.

Summary

• Arcturus Therapeutics Holdings Inc. reported a net loss of $14.08 million, or $0.52 per share, for the three months ended March 31, 2025, compared to a net loss of $26.82 million, or $1.00 per share, for the same period in 2024.
• The company's revenue decreased by $8.63 million to $29.38 million in Q1 2025, primarily due to lower collaboration revenue from CSL Seqirus and reduced grant revenue from BARDA.
• Research and development expenses decreased by $18.68 million to $34.89 million, mainly due to lower manufacturing costs for LUNAR-COVID and LUNAR-FLU programs, offset by increased costs for LUNAR-CF and LUNAR-OTC programs.
• General and administrative expenses decreased by $3.54 million to $11.32 million, primarily due to reduced share-based compensation costs.
• As of March 31, 2025, Arcturus had cash and cash equivalents, including restricted cash, of $273.83 million.
• The company drew down $15.0 million from its Wells Fargo credit line in March 2025, which was subsequently repaid in April 2025.
• KOSTAIVE (ARCT-154) received marketing authorization in Europe in February 2025.
• A Phase 1 study of ARCT-2304 (LUNAR-H5N1) completed recruitment in April 2025, and the FDA granted Fast Track Designation for ARCT-2304.
• The Phase 2 clinical program of ARCT-810 for OTC deficiency was expanded to the U.S., with the first participant initiating dosing in December 2024.
• Enrollment is advancing in the ARCT-032 Phase 2 multiple ascending dose study for cystic fibrosis.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue decreased, the company is making progress with its clinical programs and has achieved regulatory milestones for KOSTAIVE. The ongoing material weakness in internal control is a concern.

Positives

• The net loss decreased from $26.82 million in Q1 2024 to $14.08 million in Q1 2025.
• KOSTAIVE received marketing authorization in Europe in February 2025, expanding its commercial potential.
• The FDA granted Fast Track Designation for ARCT-2304, potentially expediting its development and review process.
• The Phase 2 clinical program of ARCT-810 for OTC deficiency was expanded to the U.S., indicating progress in the program.
• Enrollment is advancing in the ARCT-032 Phase 2 multiple ascending dose study for cystic fibrosis, suggesting continued development of this therapeutic candidate.

Negatives

• Revenue decreased by $8.63 million in Q1 2025 compared to Q1 2024, primarily due to lower collaboration revenue from CSL Seqirus and reduced grant revenue from BARDA.
• The company continues to incur net losses, with a loss of $14.08 million in Q1 2025.
• The company drew down $15.0 million from its Wells Fargo credit line in March 2025, indicating a need for additional financing, although it was subsequently repaid in April 2025.
• A material weakness in internal control over financial reporting related to information technology general controls (ITGCs) continues to exist as of March 31, 2025.

Risks

• The company's future capital requirements are difficult to forecast and will depend on many factors, including the progress of clinical trials, regulatory approvals, and strategic alliance agreements.
• The company may need to raise additional debt or equity financing or enter into additional partnerships to fund development.
• If the company is unable to maintain sufficient financial resources, it may need to reduce discretionary spending or discontinue the development of some or all of its programs.
• The company's ability to transition to profitability is dependent on regulatory approvals and subsequent sales of KOSTAIVE, executing on milestones within the CSL Collaboration Agreement, and identifying and developing other successful mRNA drug and vaccine candidates.
• A material weakness in internal control over financial reporting related to information technology general controls (ITGCs) continues to exist as of March 31, 2025.

Future Outlook

The company expects that its research and development efforts and associated costs will continue to be substantial over the next several years as its pipeline progresses. The company believes that its current cash position will be sufficient to meet its anticipated cash requirements through at least the next twelve months, assuming, among other things, no significant unforeseen expenses and continued funding from partners at anticipated levels.

Management Comments

• We are a messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases.
• We developed the worlds first approved self-amplifying messenger RNA (sa-mRNA) vaccine, KOSTAIVE(KOSTAIVE).
• Given current market conditions, we have made a strategic decision to streamline resources to focus on our mRNA therapeutics pipeline.

Industry Context

Arcturus Therapeutics is operating in the competitive mRNA therapeutics and vaccine space, alongside companies like Moderna and BioNTech. The approval of KOSTAIVE in Japan and Europe positions Arcturus as a key player in the self-amplifying mRNA vaccine market. The company's collaboration with CSL Seqirus further strengthens its position in the infectious disease vaccine space.

Comparison to Industry Standards

• Arcturus's collaboration with CSL Seqirus is similar to other partnerships in the mRNA space, such as the collaboration between BioNTech and Pfizer for COVID-19 vaccines.
• The company's focus on self-amplifying mRNA (sa-mRNA) technology differentiates it from companies primarily using conventional mRNA technology, like Moderna.
• The approval of KOSTAIVE in Japan and Europe marks a significant milestone, as it is the world's first approved and commercially available self-amplifying RNA (sa-mRNA) vaccine, setting a new benchmark in the industry.
• Arcturus's LUNAR delivery system is comparable to other lipid nanoparticle (LNP) delivery systems used by companies like Alnylam Pharmaceuticals for RNAi therapeutics.

Stakeholder Impact

• Shareholders: The financial results and progress in clinical programs will impact shareholder value.
• Employees: The strategic decision to streamline resources may affect employee roles and responsibilities.
• Patients: Progress in clinical trials for ARCT-810 and ARCT-032 could provide new treatment options for OTC deficiency and cystic fibrosis patients.
• Partners: The collaboration with CSL Seqirus and the BARDA contract will continue to be important for the company's vaccine development efforts.

Next Steps

• Continue enrollment in the ARCT-032 Phase 2 multiple ascending dose study for cystic fibrosis.
• Continue the Phase 2 clinical program of ARCT-810 for OTC deficiency in the U.S.
• Advance the Phase 1 study of ARCT-2304 (LUNAR-H5N1) and analyze the study results.
• Pursue regulatory filings for ARCT-154 in the US and Europe.
• Continue research and development activities for a next-generation COVID vaccine candidate.

Key Dates

Keywords

Arcturus Therapeutics, KOSTAIVE, mRNA, Vaccine, Clinical Trials, Financial Results, CSL Seqirus, BARDA, LUNAR, STARR, ARCT-154, ARCT-810, ARCT-032